Related Experiment Video

Updated: Apr 14, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K

Update of Clinical Trials of Anti-PCSK9 Antibodies

Na-Qiong Wu1, Sha Li, Jian-Jun Li

  • 1Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, 167 BeiLiShi Road, Beijing, 100037, China.

Cardiovascular Drugs and Therapy
|April 29, 2015
PubMed

Insights

Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) show promise for managing hyperlipidemia and reducing cardiovascular disease (CVD) risk. These therapies offer significant lipid-lowering effects, addressing residual risks in patients with atherosclerotic CVD.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Hyperlipidemia is a major risk factor for cardiovascular disease (CVD).
  • Statins and other lipid-lowering agents are used, but residual risks persist in atherosclerotic CVD patients.
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in low-density lipoprotein cholesterol (LDL-C) metabolism.

Purpose of the Study:

  • To review the current status and clinical trial results of monoclonal antibodies targeting PCSK9.
  • To discuss the application of PCSK9 inhibitors in managing dyslipidemia and cardiovascular outcomes.
  • To analyze the effects of PCSK9 monoclonal antibodies on lipid profiles.

Main Methods:

  • Review of existing literature and clinical trial data on PCSK9 monoclonal antibodies.
  • Analysis of pharmacological strategies for PCSK9 inhibition.
  • Evaluation of lipid-lowering efficacy and clinical outcomes.

Main Results:

  • Monoclonal antibodies targeting PCSK9 are a promising strategy for lipid management.
  • These antibodies demonstrate significant LDL-C reduction as monotherapy and in combination therapies.
  • Clinical trials support the application of PCSK9 inhibitors for improving lipoprotein profiles.

Conclusions:

  • PCSK9 monoclonal antibodies represent a significant advancement in treating dyslipidemia and reducing cardiovascular risk.
  • Targeting PCSK9 offers a novel approach to address residual cardiovascular risk in patients with atherosclerotic disease.
  • Further research and clinical application of PCSK9 inhibitors are warranted.

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.5K
Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

21.7K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
92
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
799
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
802
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603